UNSPSC 51191538: Cicletanine

This classification denotes a diuretic with the molecular formula C14H12ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CHG7QC509W, chemically known as win 90,000 but generally known as cicletanine, which bears US NIH Compound Identifier 54910. European Medicines Agency schedules Cicletanine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06237MIG. The term CICLETANINE is an International Non-Proprietary Name.

UNSPSC 51191538 Cicletanine is a Commodity code that captures pharmaceutical and chemical supply procurement by state and local governments, though the recent opportunities posted under this code show a significant mismatch with the nominal commodity name. The City of Meriden, Connecticut posted a bid solicitation (B027-15) for sodium bisulfite chemical supply for water pollution control operations, a water-treatment chemical unrelated to cicletanine. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP for generic multi-source pharmaceuticals and over-the-counter products to be distributed across participating state and local government facilities. The scope under the code spans chemical commodities for municipal utility operations and pharmaceutical products for healthcare facilities, with issuing bodies including municipal water authorities and multistate cooperative purchasing consortia serving state and local health systems and utilities.

Geographic activity centers on Connecticut and Minnesota based on recent postings. The City of Meriden solicitation (B027-15) closed July 29, 2026, requiring General Liability coverage of $1,000,000 to $2,000,000 and performance and payment bonds for the sodium bisulfite supply contract. The MMCAP RFP, with a proposal due date of March 26, 2026, seeks manufacturers to supply pharmaceuticals through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with awarded contracts effective July 1, 2026; evaluation weighting is 75 percent on price competitiveness, with vendors required to maintain $5,000,000 commercial general liability coverage and comply with current Good Manufacturing Practices and Drug Supply Chain Security Act certifications. The code shows limited recent activity and exhibits a poor fit between its nominal scope (cicletanine) and the actual commodities being procured under it in state and local markets.